Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Director comp. CC transcript
|
EXELIXIS, INC. (EXEL)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
05/02/2018 |
BW
| Exelixis Announces First Quarter 2018 Financial Results and Provides Corporate Update |
04/11/2018 |
BW
| Exelixis to Release First Quarter 2018 Financial Results on Wednesday, May 2, 2018 |
02/26/2018 |
BW
| Exelixis Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update |
01/16/2018 |
BW
| Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma |
11/21/2017 |
BW
| Exelixis Announces Webcasts of Upcoming November Investor Conference Presentations |
11/01/2017 |
BW
| Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update |
10/18/2017 |
BW
| Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017 |
09/09/2017 |
BW
| Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 |
09/06/2017 |
BW
| Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress |
08/02/2017 |
BW
| Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update |
07/17/2017 |
BW
| Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017 |
05/01/2017 |
BW
| Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update |
04/24/2017 |
BW
| Exelixis to Present at the Deutsche Bank 42nd Annual Health Care Conference on May 3 |
04/18/2017 |
BW
| Exelixis to Release First Quarter 2017 Financial Results on Monday, May 1, 2017 |
02/27/2017 |
BW
| Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update |
02/02/2017 |
BW
| Exelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017 |
07/21/2011 |
BW
| Exelixis Announces August 4th Webcast of Second Quarter 2011 Financial Results Conference Call |
07/06/2011 |
BW
| Exelixis Provides Update on Cabozantinib Development Activities |
06/06/2011 |
BW
| Exelixis' Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Metastatic Castration-Resistant Prostate Cancer |
06/05/2011 |
BW
| Exelixis' Cabozantinib Demonstrates Broad Clinical Activity in Multiple Tumor Types |
06/04/2011 |
BW
| Exelixis' Cabozantinib Demonstrates Encouraging Clinical Activity in Patients with Metastatic Ovarian Cancer |
06/01/2011 |
BW
| Exelixis Announces Webcasts of June Investor Conference Presentations |
05/31/2011 |
BW
| Reminder: Exelixis Announces Data Presentations, Webcast of Investor/Analyst Briefing and Other Activities in Conjunction with the 2011 ASCO Annual Meeting |
05/23/2011 |
BW
| Data From a Phase 1 Clinical Trial of Exelixis' Cabozantinib Published in the Journal of Clinical Oncology |
05/18/2011 |
BW
| Exelixis Launches Online Summit Featuring Expert Perspectives on Cancer Treatment Advances and ASCO Highlights |
05/13/2011 |
BW
| UPDATED: Exelixis Announces Data Presentations, Webcast of Investor/Analyst Briefing and Other Activities in Conjunction with the 2011 ASCO Annual Meeting |
05/13/2011 |
BW
| UPDATED: Exelixis Announces Data Presentations, Webcast of Investor/Analyst Briefing and Other Activities in Conjunction with the 2011 ASCO Annual Meeting |
05/09/2011 |
BW
| CORRECTING and REPLACING Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
05/03/2011 |
BW
| Exelixis Announces First Quarter 2011 Financial Results |
04/27/2011 |
BW
| Exelixis Announces May 4th Webcast of Presentation at the Deutsche Bank Securities Health Care Conference |
04/21/2011 |
BW
| Exelixis Announces May 3rd Webcast of Its First Quarter 2011 Financial Results Conference Call |
04/04/2011 |
BW
| Exelixis Announces April 7th Webcast of Presentation at the Leerink Swann Cancer Roundtable Conference |
03/15/2011 |
BW
| Exelixis Announces Exercise in Full of Option to Purchase Additional Shares and Closing of Public Offering of Common Stock |
03/09/2011 |
BW
| Exelixis Announces Pricing of $165.0 Million Public Offering of Common Stock |
|
|
|